Followers | 131 |
Posts | 29747 |
Boards Moderated | 0 |
Alias Born | 12/21/2008 |
Friday, February 05, 2010 6:48:39 AM
Date : 02/04/2010 @ 7:45PM
Source : MarketWire
Stock : Bio-Rad Laboratories (BIO)
Quote : 92.75 -1.72 (-1.82%) @ 8:00PM
Bio-Rad Laboratories, Inc. Announces Completion of Exchange Offer
HERCULES, CA -- (Marketwire) -- 02/04/10 --
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, today announced that it has completed its offer to exchange (the "Exchange Offer") up to $300 million aggregate principal amount of its 8.00% Senior Subordinated Notes due 2016 that have been registered under the Securities Act of 1933, as amended, for any and all of its outstanding 8.00% Senior Subordinated Notes due 2016 that were issued in a private placement (the "Private Notes"). All of the outstanding $300 million aggregate principal amount of the Private Notes were tendered and received prior to the expiration of the Exchange Offer at 5:00 p.m., New York City time, on February 4, 2010
This press release shall not constitute an offer to sell any securities or a solicitation of an offer to buy any securities. The Exchange Offer was made only by means of a written prospectus dated December 29, 2009
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostics markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,700 people globally and had revenues exceeding $1.7 billion in 2008. For more information, please visit www.bio-rad.com
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements
For more information contact: Christine Tsingos Vice President and Chief Financial Officer or Ron Hutton Treasurer Bio-Rad Laboratories, Inc
510-724-7000 Email Contact
Recent BIO News
- Dell, Palantir, and Erie Will Be Added to the S&P 500; Boeing Avoids Strike; Apple Event Takes Place Today • IH Market News • 09/09/2024 10:05:35 AM
- Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 • PR Newswire (US) • 09/06/2024 10:43:00 PM
- Bio-Rad’s Management to Participate in Fireside Chat During Wells Fargo’s 2024 Healthcare Conference • Business Wire • 08/22/2024 08:30:00 PM
- Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer • Business Wire • 08/20/2024 12:30:00 PM
- Bio-Rad Reports Second-Quarter 2024 Financial Results • Business Wire • 08/01/2024 08:15:00 PM
- Bio-Rad to Report Second Quarter Financial Results on Thursday, August 1, 2024 • Business Wire • 07/17/2024 08:30:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 10:37:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 05:42:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/13/2024 09:50:32 PM
- Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group • Business Wire • 05/30/2024 01:00:00 PM
- Bio-Rad’s Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference • Business Wire • 05/23/2024 08:15:00 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/09/2024 08:30:20 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/08/2024 08:38:02 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:31:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:18:26 PM
- Bio-Rad Reports First-Quarter 2024 Financial Results • Business Wire • 05/07/2024 08:15:00 PM
- Bio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference • Business Wire • 05/01/2024 01:00:00 PM
- Bio-Rad Announces Life Science Group Management Changes • Business Wire • 04/26/2024 12:30:00 PM
- Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 • Business Wire • 04/18/2024 01:00:00 PM
- Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay • GlobeNewswire Inc. • 04/11/2024 09:30:00 PM
- Bio-Rad’s Chief Operating Officer Andrew Last to Retire • Business Wire • 04/10/2024 08:15:00 PM
- Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer • Business Wire • 03/20/2024 12:30:00 PM
- Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day • Business Wire • 02/22/2024 09:30:00 PM
- Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results • Business Wire • 02/15/2024 09:15:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM